Method of identification of cells that show sensitivity to modulation of signalingh mediated by fibroblast growth factor receptor or a variant thereof

A method of using or the use of phosphorylation identification in FRS-2, a variant thereof or a tyrosine comprising fragment thereof, as a biomarker for cells, tissues or organs that show hyperactive, especially constitutively activated, FGF-R signaling, especially that are treatable with inhibitors of FGF-R or a variant thereof and that are responsive to such inhibitors, said method or use comprising determining the presence of phosphorylated tyrosine in FRS-2, in a variant thereof or in a tyrosine comprising fragment thereof from a biological sample with a biospecific recognition reagent capable of recognizing phosphotyrosine in FRS-2, a positive finding of phosphorylation indicating hyperactive, especially constitutively activated, FGF-R signaling

A kit comprising a biospecific recognition reagent for FGF-R or a variant thereof and a biospecific recognition reagent capable of recognizing a phosphorylated form of FRS-2 or of a variant or of a tyrosine comprising fragment thereof for use in the identification of cells from a biological sample that are sensitive to modulation, especially inhibition, of signaling into which a Fibroblast Growth Factor Receptor (FGF-R) is involved, said kit comprising means for determining the phosphorylation status of an FRS-2, a variant thereof or a tyrosine comprising fragment thereof in a biological sample as biomarker for such sensitivity to inhibition.

A biospecific recognition reagent capable of recognizing a phosphorylated form of FRS-2 or of a variant or of a tyrosine comprising fragment thereof for use in the identification of cells that show sensitivity to modulation, especially inhibition, of signaling into which a Fibroblast Growth Factor Receptor (FGF-R) or a variant thereof is involved, especially of cells that show hyperactivity, more especially constitutive activation of FGF-R signaling.

13-14. (canceled)

A method of diagnosing a disease responsive to treatment with an inhibitor of FGF-R signaling, comprising identifying a phosphorylated form of FRS-2, of a variant thereof or of a tyrosine comprising fragment thereof in a biological sample from a patient.